newsfilter
← Latest News
GlobeNewswire·

Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA)Completed $15 million registered direct offering and $125 million private placement with potential for up to an